Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2]. |
In vivo | Tamtuvetmab, administered intravenously at a concentration of 5 mg/mL and volumes ranging from 7.5 to 30 mL over 15 to 30 minutes, demonstrates in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). However, it is associated with adverse effects including vomiting, weight loss, diarrhea, lethargy, reduced appetite, and anorexia [1]. |
Alias | AT-005, AT005 |
Cas No. | 1608122-71-9 |
Storage | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.